PEAK6’s Gilead Sciences GILD Stock Holding History

PEAK6’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-34,100	Closed	-$3.78M	–	3135
2025 Q2	$3.78M	Sell	34,100 -140,900	-81%	-$15M	0.01%	1108
2025 Q1	$19.6M	Buy	175,000 +145,000	+483%	+$15M	0.04%	345
2024 Q4	$2.77M	Buy	+30,000	New	+$2.7M	0.01%	1232

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PEAK6's GILD Position: Q2 2026 in Review

PEAK6 sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 7,597 shares — an estimated $1M sold.

PEAK6 first reported a position in GILD in Q1 2026 and held it in 1 quarter. The position peaked at $1.06M in Q1 2026. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

PEAK6 reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
PEAK6 sold 7,597 Gilead Sciences shares in Q2 2026, an estimated $1M.
PEAK6 first reported a position in Gilead Sciences in Q1 2026 and held it in 1 quarter.
PEAK6's Gilead Sciences position peaked at $1.06M in Q1 2026.
2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on PEAK6's 13F filing for Q2 2026, filed 13 Aug 2026.